Japanese pharmaceutical giant Sumitomo Pharma has filed for regulatory approval of its innovative stem cell-based therapy for Parkinson’s disease, marking a major milestone in the global race to develop a regenerative treatment for the debilitating neurological disorder.
The submission was made to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and represents the world’s first formal application for a Parkinson’s therapy based on induced pluripotent stem cells (iPSCs). If approved, the treatment could revolutionize care for millions living with Parkinson’s worldwide.
The therapy involves transplanting dopamine-producing neurons derived from iPSCs into the brains of patients suffering from Parkinson’s, a progressive neurodegenerative condition characterized by tremors, stiffness, and impaired movement caused by the loss of dopamine-producing cells in the brain. Traditional treatments such as levodopa and deep brain stimulation can alleviate symptoms but do not halt or reverse the underlying disease progression.
Sumitomo’s treatment, developed in collaboration with Kyoto University’s Center for iPS Cell Research and Application (CiRA), aims to restore lost neurological function by replacing damaged neurons with healthy, lab-grown ones. Clinical trials in Japan have shown promising results, with patients reporting improved motor function and quality of life without major safety concerns.
Dr. Masaru Taniguchi, Chief Medical Officer at Sumitomo Pharma, stated, “This is a historic step forward. For decades, we have treated Parkinson’s symptoms — but now we are closer than ever to repairing the root cause.”
If approved, the therapy would not only be the first of its kind but would also pave the way for a new era of regenerative medicine in neurology. The company has hinted at plans to pursue approvals in the U.S. and Europe after Japanese clearance.
Parkinson’s disease affects more than 10 million people globally, with incidence rates expected to rise due to aging populations. The development of cell-based therapies offers hope to those with advanced stages of the disease, where conventional treatments often fail.
Sumitomo’s submission now begins a rigorous review process, but optimism is high that a new frontier in Parkinson’s treatment may soon become a reality.
